Johns Hopkins ABX Guide
Rifaximin
INDICATIONS
FDA
FDA
- Treatment of traveler’s diarrhea due to noninvasive E. coli
- Reduction in risk of overt hepatic encephalopathy recurrence
- Treatment of irritable bowel syndrome-diarrhea predominant (IBS-D)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- C. difficile-associated diarrhea (prevention, or second-line treatment)
- Adjunctive ’rifaximin chaser’ after vancomycin for multiply recurrent CDI (limited evidence, not currently recommended in IDSA Guideline).
- Small bowel bacterial overgrowth
- Prevention of traveler’s diarrhea
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: July 3, 2026
Citation
Dzintars, Kathryn, and Paul A Pham. "Rifaximin." Johns Hopkins ABX Guide, The Johns Hopkins University, 2026. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540485/9/Rifaximin.
Dzintars K, Pham PA. Rifaximin. Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540485/9/Rifaximin. Accessed July 11, 2026.
Dzintars, K., & Pham, P. A. (2026). Rifaximin. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540485/9/Rifaximin
Dzintars K, Pham PA. Rifaximin [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. [cited 2026 July 11]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540485/9/Rifaximin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Rifaximin
ID - 540485
A1 - Dzintars,Kathryn,Pharm.D., BCPS
AU - Pham,Paul,Pharm.D.
Y1 - 2026/07/03/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540485/9/Rifaximin
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
